High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1463-1472

  Stemmer, S M ^a   Cagnoni, P J ^a   Shpall, E J ^a   Bearman, S I ^a   Matthes, S ^a   Dufton, C ^a   Day, T ^a   Taffs, S ^a   Hami, L ^a   Martinez, C ^a   Purdy, M H ^a   Arron, J ^a   Jones, R B ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 9244238682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1463     Document Type: Article

References (40)

1. Schabel FM: Animal models as predictive systems, in Cancer Chemotherapy, Fundamental Concepts and Recent Advances. Chicago, IL, Year Book Medical, 1975, pp 323-355
2. Teicher B, Holden SA, Cucchi CA, et al: Combination of N,N′,N″-triethylenethiophosphamide and cyclophosphamide in vitro and in vivo. Cancer Res 48:94-100, 1988
3. Frei E III, Cucchi C, Rosowsky A, et al: Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158-2162, 1985
4. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
5. Jones RB, Shpall EJ, Ross M, et al: AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for the treatment of breast cancer. Current results. Proc Am Soc Clin Oncol 7:121, 1990 (abstr 30)
6. Dunphy FR, Spitzer G: Use of very high dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 84:128-129, 1992
7. Grad G, Lane N, Zimmerman T, et al: High-dose chemotherapy and autologous stem cell support in breast cancer: The University of Chicago experience. Proc Am Soc Clin Oncol 13:73, 1994 (abstr 94)
8. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102-110, 1992
9. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 177:655-667, 1979
10. Horwitz SB: Mechanism of action of Taxol. Trends Pharmacol Sci 13:134-136, 1992
11. Milas L, Hunter NR, Kurdoglu B, et al: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 35:297-303, 1995
12. McCloskey DE, Davidson NE: Paclitaxel-induced programmed cell death in human breast cancer cells. Proc Am Assoc Cancer Res 36:416, 1995 (abstr 2482)
13. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
14. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
15. Younes A, Sarris A, Melnyk A, et al: Three-hour paclitaxel infusion in patients with refractory 2nd relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:583-587, 1995
16. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
17. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
18. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993
19. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant chemotherapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
20. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologie study. J Clin Oncol 9:1692-1703, 1991
21. + peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 12:28-36, 1994
22. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
23. Jones RB, Matthes S, Shpall EJ, et al: Acute lung injury following high-dose cyclophosphamide, cisplatin and BCNU. Pharmacodynamic evaluation of BCNU. J Natl Cancer Inst 85:640-647, 1993
24. Jones RB, Matthes S, Dufton C, et al: Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Res Treat 26:S11-S17, 1993
25. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
26. Rowinsky EK, Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48:4093-4100, 1988
27. Liebmann JE, Cook JA, Lipshultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993
28. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
29. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
30. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
31. Sarosy G, Reed E: Taxol dose intensification and its clinical implications. J Natl Med Assoc 85:427-431, 1993
32. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1995
33. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer [see comments]. J Clin Oncol 12:241-248, 1994
34. Alberts DS, Krutzsch M, Wymer J, et al: Experimental rationale for 24 vs 3 hour paclitaxel infusion schedules in the treatment of advanced ovarian cancer. Proc Am Assoc Cancer Res 36:363, 1995 (abstr 2164)
35. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
36. Goldberg HL, Vannice SB: Pneumonitis related to treatment with paclitaxel. J Clin Oncol 13:534-535, 1995
37. Brown T, Havlin K, Weiss G, et al: A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267, 1991
38. Rowinsky EK, Wright M, Monsarrat B, et al: Taxol: Pharmacology, metabolism and clinical implications, in Workman P, Graham MA (eds): Pharmacokinetics and Cancer Chemotherapy. Plainview, NY, Cold Spring Harbor Laboratory, 1993, pp283-304
39. Beijnen JH, Huizing MT, ten Bokkel Huinink, et al: Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel. Semin Oncol 21:53-62, 1994
40. Gianni L, Keams CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995